Abstract Number: 1988 • ACR Convergence 2023
Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis
Background/Purpose: Intraarticular (IA) corticosteroids are generally considered safe and effective to treat osteoarthritis of the knee (OAK) but may cause hyperglycemia that may last for…Abstract Number: 2242 • ACR Convergence 2023
Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes
Background/Purpose: Psoriatic arthritis (PsA) is a chronic and progressive disease characterized by high rates of early joint erosions, which have been associated with impaired quality…Abstract Number: 2487 • ACR Convergence 2023
Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
Background/Purpose: Ianalumab is a novel defucosylated human IgG1 mAb targeting the receptor for B cell Activating Factor belonging to the TNF Family (BAFF-R) providing potent…Abstract Number: 0440 • ACR Convergence 2023
Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). However, data on predictive biomarkers associated with therapeutic response…Abstract Number: 0749 • ACR Convergence 2023
Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study
Background/Purpose: Sprifermin, recombinant human fibroblast growth factor 18 (rhFGF-18), is being investigated as a potential disease-modifying osteoarthritis drug. The Phase 2 FORWARD study demonstrated that…Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…Abstract Number: 1422 • ACR Convergence 2023
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
Background/Purpose: Risankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinical trials.The objective of this integrated data…Abstract Number: 1512 • ACR Convergence 2023
Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial
Background/Purpose: New medicines in SLE have not met endpoints in placebo-controlled RCTs when other evidence indicates they are effective. Reasons suggested are inclusion of patients…Abstract Number: 1991 • ACR Convergence 2023
Therapeutic Efficacy of Intra Articular Injection of Human Bone Marrow Derived Mesenchymal Stem Cells in Knee Osteoarthritis; Randomized, Double-blind, Placebo-controlled Clinical Trial
Background/Purpose: Osteoarthritis (OA) is severe and intractable musculoskeletal disease that eventually leads to joint failure and pain due to inflammation and joint injury. Mesenchymal stem…Abstract Number: 2245 • ACR Convergence 2023
Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study
Background/Purpose: Risankizumab (RZB) is an optimized IL-23 inhibitor (IL-23i) currently approved for the treatment of plaque psoriasis (PsO), PsA, and Crohn's disease. In a post…Abstract Number: 2488 • ACR Convergence 2023
Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial
Background/Purpose: ABBV-599 is a novel combination of elsubrutinib (ELS; a selective BTK inhibitor) and upadacitinib (UPA; a JAK inhibitor) that targets non-overlapping signaling pathways associated…Abstract Number: 0443 • ACR Convergence 2023
The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis
Background/Purpose: TNFα inhibition is a cornerstone of therapy for rheumatologic disease, yet there is no orally administered TNFα inhibitor available. A novel oral TNFα inhibitor…Abstract Number: 0775 • ACR Convergence 2023
Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…Abstract Number: 1124 • ACR Convergence 2023
A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China
Background/Purpose: Hemay005 is an orally active selective PDE4 inhibitor under clinical development for treating chronic inflammatory diseases. Hemay005 significantly inhibits the activation of T lymphocytes,…Abstract Number: 1423 • ACR Convergence 2023
Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 44
- Next Page »